When: Confirmed weekly close <$180 on >5M volume with MACD bearish cross

Then: Trim additional 10-15% of PM position

When: Price tests $172-176 zone (200 SMA at $172.74)

Then: Add first tranche on reduced size; hard stop <$172

When: Confirmed weekly reversal candle with volume capitulation, MACD compression toward zero, RSI ≤35

Then: Add second tranche with confirmation

When: Confirmed close >$188.56 on >5M volume with positive MACD histogram and RSI >50

Then: Add at 0.5x normal notional

When: Confirmed weekly close <$170 on volume (200 SMA break)

Then: Exit remaining position

HOLD existing position; do not add at $184; wait for confirmed re-entry signal at $172 (with RSI >45 and MACD histogram compressing toward zero) or confirmed breakout above $188.56

• Risk per share from $184 to $182 stop is $2 (1.1% of position); reward from $184 to $190 is $6 (3.3%)—asymmetric but stop sits at lower Bollinger Band level tested September 4th at $182.23 where liquidity sweeps and stop hunts occur
• Q2 2026 was $11.19 billion (strongest single quarter in PM history) but TTM EPS is depressed by ~$2.3 billion extraordinary charges from 2024 Russia exit and Swedish Match integration; '26% embedded growth' is partly lapping a one-time hit
• Reported organic growth decelerating: Q1 grew 0.1%, H1 grew 1.7% against 8.6% CAGR target; smoke-free mix shift not yet showing cleanly in top line
• MACD at -0.67 with confirmed bearish crossover and expanding negative histogram is early innings of momentum deterioration, not late innings; small reading early in bearish phase has most room to extend
• PM's 70% non-USD revenue base creates translation exposure on reported EPS—FX hedge at subsidiary level does not hedge balance sheet translation risk; DXY spike creates 3-5% EPS headwind overnight
• FDA Zyn authorization rally from $150 to $200 already digested by institutional positioning; Motley Fool mea culpa is typically a late-stage sentiment signal, not early-stage
• ATR compression resolves based on catalyst flow, not inherently bullish; current setup has FDA catalyst pushing one way, MACD bearish crossover/Iran conflict/oil shock/flattening 50 SMA pushing other
• In true liquidity crisis (Iran escalation + oil spike + equity support breaks simultaneously), PM's 0.40 beta does not protect—marginal bid for quality compounders disappears when margin calls hit
• Conservative entry at $172 with stop at $168 targets 2.3% downside if stop triggers—better risk/reward than chasing at $184 with stop at $182 (1.1% risk at worse cost basis)
• If $172 level never gets tested and price chops sideways $180-$190, portfolio can absorb missing the rally; opportunity cost of liquidity-swept exit at $181.50 is unacceptable

→ vs aggressive: MACD at -0.67 is not a 'rounding error'—a small MACD reading early in a bearish phase has the most room to extend; calling it insignificant is backwards risk management

→ vs aggressive: Q2 2026 strength ($11.19B) is partly lapping ~$2.3B extraordinary charges from 2024 Russia exit and Swedish Match integration; forward P/E '26% growth' embeds accounting recovery, not necessarily organic acceleration

→ vs aggressive: FX 'hedged at subsidiary level' is translation exposure, not a hedge—70% non-USD revenue means DXY spike creates 3-5% overnight EPS headwind; macro setups change

→ vs aggressive: ATR compression has no inherent bullish bias; framing it as bullish from this setup (MACD bearish crossover + Iran conflict + oil shock) is selection bias

→ vs aggressive: Stop at $182 on lower Bollinger Band is structurally flawed—level was tested September 4th at $182.23 and creates liquidity sweep zone; 1.1% loss from liquidity-driven exit is the wrong loss to take

→ vs aggressive: FDA catalyst already digested into 30% rally from $150-$200; institutional smart money already positioned and looking for exits; Motley Fool mea culpa is late-stage sentiment signal

→ vs aggressive: Recession odds at 8% framing dismisses liquidity crisis scenario where PM's 0.40 beta does not protect; Barron's headlines about Iran conflict being ignored + oil surging + Dow breaking support = closer to liquidity event than normal correction

Maintain core position; stage entry into new exposure at two trigger points—buy-the-dip at $181–$183 zone with daily close stop below $179, and trend-resumption entry at $187 reclaim with stop at $183. Keep sizing at 1–2% portfolio weight.

• Q1 2026 0.1% growth was distorted by Swedish Match integration tough comps; Q2's 3.2% growth on record revenue print is real evidence the underlying business is not in structural deceleration
• YTD reported revenue growth at 1.7% is materially below the 8.6% three-year CAGR and that gap needs explanation, but does not prove the smoke-free thesis is failing
• MACD at -0.67 is a warning signal, not a verdict on trend collapse; early-stage negative MACD is not the most dangerous phase statistically
• ATR compression could resolve in either direction and warrants asymmetric position sizing through options or staged entries
• Stop placement at $182 is technically problematic because that level was tested four trading days ago and held on a bounce; stops should reference daily closes below structural levels rather than tick-throughs
• FX translation exposure is real but bounded; a 5% DXY rally would generate roughly a 2–3% EPS headwind, not 3–5% overnight
• FDA Zyn authorization is a genuine and fresh catalyst; 'smart money has already positioned' is speculation, not market structure
• The Aggressive Analyst's catalyst-driven upside story has not yet been confirmed by price action; the Conservative Analyst's momentum deterioration thesis is contradicted by long-term trend structure
• Neutral read on macro: base case favors defensive outperformance, tail presents a real but contained liquidity event risk

→ vs aggressive: Stop placement at $182 is structurally flawed—the level was tested four trading days ago and held on a bounce, making it vulnerable to liquidity sweeps; stops should reference daily closes below $181.50 or the prior swing low at $182.23, not tick-throughs

→ vs aggressive: MACD at -0.67 with expanding negative histogram is a real momentum warning signal, not a rounding error to be dismissed in a name trading near $185

→ vs aggressive: FDA catalyst absorption has not been confirmed by price action—the claim that 'smart money has already positioned and is looking for exits' is speculation dressed as market structure

→ vs conservative: $172 entry is not a near-certainty or prerequisite for action; waiting passively for a specific price level while an FDA catalyst is in the tape is also a form of mistake

→ vs conservative: Trade is not 'structurally flawed'—only the specific stop placement at $182 needs adjustment; the entry thesis itself survives critique

→ vs conservative: Early-stage negative MACD is not statistically the most dangerous phase; the most negative readings typically occur at the end of sharp pullbacks, not the beginning

→ vs conservative: The 3–5% overnight EPS FX headwind uses the high end of a plausible range and overstates the tail risk; a 5% DXY rally implies roughly 2–3% EPS impact, which is bounded